Patents Assigned to Merck Sharp & Dohme
  • STAPLED OLEFIN CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS
    Publication number: 20230270825
    Abstract: The stapled peptides of the present invention, and pharmaceutically acceptable salts thereof, are co-agonists of the glucagon and GLP-1 receptors, and may be useful in the treatment, prevention and suppression of diseases mediated by the glucagon receptor and the GLP-1 receptor, including but not limited to, metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.
    Type: Application
    Filed: December 18, 2020
    Publication date: August 31, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Elisabetta Bianchi, Qiaolin Deng, Songnian Lin, Federica Orvieto, Anandan Palani, Antonello Pessi, Tomi K. Sawyer
  • AFFINITY MATURED ANTI-LAP ANTIBODIES AND USES THEREOF
    Publication number: 20230272056
    Abstract: Provided herein are anti-LAP antibodies (e.g., recombinant humanized, chimeric, and human anti-LAP antibodies) or antigen binding fragments thereof which have therapeutically beneficial properties, such as binding specifically to LAP-TGF?1 on cells but not to LAP-TGF?1 in extracellular matrix, as well as compositions including the same. Also provided are uses of these antibodies or antigen binding fragments in therapeutic applications, such as in the treatment of cancer, and diagnostic applications.
    Type: Application
    Filed: April 8, 2021
    Publication date: August 31, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Chung-Ming Hsieh, Michelle Castor, Ming-Tang Chen, Alan C. Cheng, Scott A. Hollingsworth, Veronica M. Juan, Madhura Shidhore, Song Yang, Renee C.T. Moore
  • HPV VACCINE
    Publication number: 20230270850
    Abstract: The present disclosure provides, among other things, a pharmaceutical composition that includes a lipid nanoparticle adjuvant and an anti-human papillomavirus (HPV) comprising HPV virus-like particles (VLPs) of at least one type of human papillomavirus (HPV) selected from the group consisting of HPV types: 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 73, and 82.
    Type: Application
    Filed: March 10, 2023
    Publication date: August 31, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Andrew J. Bett, John P. Bilello, Amy S. Espeseth, Tong-Ming Fu, Marian E. Gindy
  • Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same
    Patent number: 11739143
    Abstract: The invention provides methods for using and compositions of humanized antibodies that bind tau protein that is phosphorylated at the serine at position 413.
    Type: Grant
    Filed: December 15, 2020
    Date of Patent: August 29, 2023
    Assignees: TEIJIN PHARMA LIMITED, MERCK SHARP & DOHME LLC
    Inventors: Hiroshi Eguchi, Takashi Murakami, Naoko Namiki, Akira Tanokura, Jeanne E. Baker, Sophie Parmentier Batteur, Angela Marie Jablonski, Daniel Stephen Malashock, Carl Mieczkowski, Gopalan (Raghu) Raghunathan
  • Oxazolidinones as TarO inhibitors
    Patent number: 11738010
    Abstract: Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a ?-lactam antibiotic.
    Type: Grant
    Filed: July 26, 2021
    Date of Patent: August 29, 2023
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: John P. Caldwell, Reynalda De Jesus, Fa-Xiang Ding, Charles J. Gill, Ginny Dai Ho, Sookhee N. Ha, Sandra J. Koseoglu, Marc A. Labroli, Sang Ho Lee, Christina Madsen-Duggan, Mihir Mandal, Terry Roemer, Jing Su, Christopher Michael Tan, Zheng Tan, Haifeng Tang, Hao Wang, Christine Yang, Shu-Wei Yang
  • STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20230263887
    Abstract: The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof. In some embodiments the formulations of the invention comprise between 5-200 mg/mL anti-PD-1 antibody, or antigen binding fragment thereof. The invention further provides methods for treating various cancers with stable formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by intravenous or subcutaneous administration.
    Type: Application
    Filed: March 10, 2023
    Publication date: August 24, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Manoj K. Sharma, Wendy Benjamin, Sarita Mittal, Ashwin Basarkar, Chakravarthy Nachu Narasimhan, Ramesh S. Kashi, Mohammed Shameem, Soumendu Bhattacharya, William P. Forrest, Jr., Yogita Krishnamachari
  • RIPK1 INHIBITORS AND METHODS OF USE
    Publication number: 20230265094
    Abstract: Described herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof. The compounds of Formula (I) act as RIPK1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for RIPK1-related diseases.
    Type: Application
    Filed: June 7, 2021
    Publication date: August 24, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Jenny Lorena Rico Duque, Phieng Siliphaivanh, Xavier Fradera, Zachary G. Brill, Jing SU
  • METHOD FOR DETECTING CYTOMEGALOVIRUS (CMV) AND MEASURING AND QUANTIFYING PENTAMERIC COMPLEX USING AN INDIRECT SANDWICH ELISA
    Publication number: 20230266320
    Abstract: The present invention relates to a method of detecting the presence of Cytomegalovirus and measuring antigenicity through detection and quantification of a pentameric complex by an indirect sandwich ELISA assay which ensures an appropriate concentration of this critical glycoprotein complex is present in the vaccine.
    Type: Application
    Filed: November 20, 2020
    Publication date: August 24, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Cindy J. Pauley, Lawrence William Dick, Jr., Mary Lillian Shank Retzlaff, Matthew C. Troutman, Lynne Ireland Denny, Qiana M. Wilson, Kuo-Chang Yin
  • HIGH AFFINITY ANTIBODIES TARGETING TAU PHOSPHORYLATED AT SERINE 413
    Publication number: 20230265175
    Abstract: Provided herein are high affinity antibodies or antigen binding fragments thereof that specifically bind to human tau-pS413. Also provided are compositions, kits, methods, and uses involving such antibodies or antigen binding fragments thereof.
    Type: Application
    Filed: June 23, 2021
    Publication date: August 24, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Jeanne E. Baker, Sophie Parmentier Batteur, Ming-Tang Chen, Alan C. Cheng, Chung-Ming Hsieh, Carl Mieczkowski, Sokreine Suon
  • CYCLIC CYANOENONE DERIVATIVES AS MODULATORS OF KEAP1
    Publication number: 20230257371
    Abstract: The present invention relates to cyclic cyanoenone derivatives of Formula (I) or pharmaceutically acceptable salts or solvates thereof, wherein R1, R2, R3, R4 and m are as defined herein. The present invention also relates to pharmaceutical compositions comprising the cyclic cyanoenone derivatives of Formula (I) and to their use in therapy.
    Type: Application
    Filed: July 15, 2021
    Publication date: August 17, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Michael D. Altman, David A. Canditio, Alec H. Christian, Ornella Di Pietro, Min Lu, Umar Faruk Mansoor, Katrina Marie Mennie, Andrew J. Musacchio, Anandan Palani, Michael H. Reutershan, David Matthew Shaw, Ping Lui, Stephen St-Gallay
  • MODULAR BLENDER AND METHOD OF USING SAME
    Publication number: 20230256401
    Abstract: A blender includes a proximal section having a proximal upper housing and a proximal lower housing, a distal section having a distal upper housing and a distal lower housing, at least one intermediate section disposed between the proximal section and the distal section and coupleable thereto, each of the at least one intermediate section including an intermediate upper housing and an intermediate lower housing, a shaft extending through the proximal section, the distal section and the at least one intermediate section, and at least one blade disposed on the shaft.
    Type: Application
    Filed: April 26, 2021
    Publication date: August 17, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: William Blincoe, James C. DiNunzio, M. Sebastian Escotet Espinoza, Sung Woo Kim, Graciela Terife
  • CYCLOPENTAPYRROLE OREXIN RECEPTOR AGONISTS
    Publication number: 20230257348
    Abstract: The present invention is directed to cyclopentapyrrole, furopyrrole and azabicycloheptane compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: August 16, 2021
    Publication date: August 17, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Stephane L. Bogen, Dane James Clausen, Michael T. Rudd, Dong Xiao, Dexi Yang
  • METHODS FOR TREATING CANCER OR VON-HIPPEL LINDAU DISEASE USING A COMBINATION OF A PD-1 ANTAGONIST, A HIF-2 ALPHA INHIBITOR, AND LENVATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
    Publication number: 20230250182
    Abstract: Provided herein are methods of treating cancer (e.g., RCC) or von-Hippel Lindau disease, which comprise administering to a human patient in need thereof: (a) a PD-1 antagonist; (b) a HIF-2? inhibitor; and (c) lenvatinib, or a pharmaceutically acceptable salt thereof. Also provided are kits containing such agents and uses of therapeutic combinations of such agents for the treatment of cancer.
    Type: Application
    Filed: June 21, 2021
    Publication date: August 10, 2023
    Applicants: Merck Sharp & Dohme LLC, Eisai R&D Management Co., Ltd.
    Inventors: Rodolfo Fleury Perini, Elaine M. Pinheiro, Jacqueline Willemann-Rogerio
  • TREATMENT OF METASTATIC PANCREATIC ADENOCARCINOMA
    Publication number: 20230242644
    Abstract: A method of treating metastatic pancreatic adenocarcinoma in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of each of a peptide set forth in SEQ ID NO: 1, an anti PD-1 and a chemotherapy, thereby treating the metastatic pancreatic adenocarcinoma.
    Type: Application
    Filed: February 14, 2023
    Publication date: August 3, 2023
    Applicants: BioLineRx Ltd., Merck Sharp & Dohme Corp.
    Inventors: Abi VAINSTEIN-HARAS, Ella SORANI, Irit GLIKO-KABIR, Osnat BOHANA-KASHTAN, Amnon PELED
  • ADJUVANTED VACCINES
    Publication number: 20230234850
    Abstract: Vaccine formulations are described comprising physically separated, lyophilized antigens and adjuvant components, which may be in lyoparticle form, as well as methods of using and making such formulations. Reconstituted formulations are also described.
    Type: Application
    Filed: February 22, 2023
    Publication date: July 27, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Akhilesh Bhambhani, Muneeswara Babu Medi, Maya Salnikova, William James Smith, David S. Thiriot
  • Process for making beta 3 agonists and intermediates
    Patent number: 11708371
    Abstract: The present invention is directed to processes for preparing beta 3 agonists of Formula (I) and Formula (II) and their intermediates. The beta 3 agonists are useful in the treatment of certain disorders, including overactive bladder, urinary incontinence, and urinary urgency.
    Type: Grant
    Filed: January 22, 2021
    Date of Patent: July 25, 2023
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: John Y. L. Chung, Kevin Campos, Edward Cleator, Robert F. Dunn, Andrew Gibson, R. Scott Hoerrner, Stephen Keen, Dave Lieberman, Zhuqing Liu, Joseph Lynch, Kevin M. Maloney, Feng Xu, Nobuyoshi Yasuda, Naoki Yoshikawa, Yong-Li Zhong
  • 5-OXOPYRROLIDINE-3-CARBOXAMIDES AS NAV1.8 INHIBITORS
    Publication number: 20230227405
    Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.
    Type: Application
    Filed: June 14, 2021
    Publication date: July 20, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Ashok Arasappan, Ian M. Bell, Jason Michael Cox, Michael J. Kelly, III, Mark E. Layton, Hong Liu, Jian Liu, Akshay A. Shah, Michael David VanHeyst
  • 2-OXO-OXAZOLIDINE-5-CARBOXAMIDES AS NAV1.8 INHIBITORS
    Publication number: 20230227441
    Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.
    Type: Application
    Filed: June 14, 2021
    Publication date: July 20, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Ashok Arasappan, Ian M. Bell, Christopher James Bungard, Christopher S. Burgey, Jason Michael Cox, Deodial Guy Guiadeen, III, Michael J. Kelly, III, Mark E. Layton, Hong Liu, Jian Liu, James T. Olsen, James J. Perkins, Jeffrey W. Schubert, Akshay A. Shah, Shawn J. Stachel, Michael David VanHeyst, Zhe Wu
  • High affinity antibodies targeting tau phosphorylated at serine 413
    Patent number: 11702467
    Abstract: Provided herein are high affinity antibodies or antigen binding fragments thereof that specifically bind to human tau-pS413. Also provided are compositions, kits, methods, and uses involving such antibodies or antigen binding fragments thereof.
    Type: Grant
    Filed: June 23, 2021
    Date of Patent: July 18, 2023
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Jeanne E. Baker, Sophie Parmentier Batteur, Ming-Tang Chen, Alan C. Cheng, Chung-Ming Hsieh, Carl Mieczkowski, Sokreine Suon
  • Aza-benzothiophene compounds as STING agonists
    Patent number: 11702430
    Abstract: Compounds of general formula (I), and their pharmaceutically acceptable salts, wherein R1, R2, R3, R5, R6, R8, R9, A, X1, X2, and X3 are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are compositions comprising such compounds, processes for the synthesis of such compounds, and to uses of such compounds, including administration of such compounds to induce immune response, to induce STING-dependent type I interferon production, and/or to treat a cell proliferation disorder, such as cancer.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: July 18, 2023
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Michael D. Altman, Brandon D. Cash, Jared N. Cumming, Duane E. DeMong, Andrew M. Haidle, James P. Jewell, Matthew A. Larsen, Min Lu, Ryan D. Otte, Brandon M. Taoka, Benjamin Wesley Trotter, Quang T. Truong